NCT05322889

Who might be able to join this trial:

• You have been diagnosed with ovarian or breast cancer, and your doctor has planned for you to receive a chemotherapy drug called paclitaxel as part of your standard care
• You are a woman aged 18 to 80 years old
• If you have had cancer spread to your brain, you must have finished radiation therapy or surgery for it more than 2 weeks before the screening visit, be neurologically stable with no new symptoms or changes on brain scans, and if you take steroids for this, you must have been on a steady dose for at least 2 weeks before screening
• You are willing and able to follow the study procedures and requirements
• You have given written consent to take part before any study procedures begin

Who may not be able to join:

• You have been previously diagnosed with, or currently have, nerve pain in your hands or feet (peripheral neuropathic pain)
• You have other severe pain that could make it difficult to assess nerve pain
• You scored 4 or higher on a nerve pain questionnaire called the DN4 (confirm with trial site)
• You have received chemotherapy (including paclitaxel) within the last 5 years — although treatment with cyclophosphamide and an anthracycline as part of an ongoing adjuvant or neo-adjuvant regimen is allowed
• You are currently receiving, or planning to receive, paclitaxel in combination with other chemotherapy drugs, such as platinum-based drugs — though paclitaxel combined with certain targeted therapies (trastuzumab with or without pertuzumab) is allowed
• You have a primary brain tumour, or cancer that has spread to your brain and is causing unstable neurological symptoms
• You have had a previous bad reaction or intolerance to a type of blood pressure medication called angiotensin II receptor blockers (AT1-receptor blockers)
• Your blood pressure is too low (below 110/70 mmHg based on an average of 3 measurements taken after sitting for at least 5 minutes)
• You are currently taking any of the following medications: aliskiren, digoxin, or ACE-inhibitor blood pressure medications — though switching from an ACE-inhibitor to telmisartan at the start of the trial may be allowed (confirm with trial site)
• You are currently taking certain antidepressants (such as amitriptyline), anti-epileptic medicines (such as gabapentin, pregabalin, or lamotrigine), duloxetine, glutamine, or vitamin E
• You are currently taking a blood pressure medication called telmisartan at the time of your screening visit
• Your liver or kidney function is not within acceptable levels based on blood tests at your screening visit (confirm specific values with trial site)
• You have a stomach or bowel condition that could affect how your body absorbs medication, such as ulcerative disease, uncontrolled nausea, vomiting, diarrhoea, a malabsorption condition, or previous removal of part of your small bowel
• You have a history of or currently have a severe psychiatric or psychological illness
• You have uncontrolled chest pain (angina) or significant heart failure with moderate to severe symptoms
• You currently have another active cancer, other than the one being treated in this study — though some exceptions may apply, such as a cancer that was fully treated and has not returned in the past 2 years, or certain fully removed skin cancers or non-invasive cancers (confirm with trial site)
• You have other significant uncontrolled or serious health conditions that could affect your safety or the results of the study
• You have a current or past active Hepatitis B, Hepatitis C, or HIV infection, confirmed by test results no older than 8 weeks

Important: Always verify eligibility with the trial site directly before applying.